behalf of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD)
Study Investigators. Effects of Fenofibrate Treatment on Cardiovascular
Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components
of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in
Diabetes (FIELD) Study. Diabetes Care 32:493-498.
2. Miller M, Cannon CP, Murphy SA et al, PROVE-IT TIMI 22 Investigators.
Impact of triglyceride levels beyond low-density lipoprotein cholesterol after
acute coronary syndrome in the PROVE-IT TIMI 22 trial. J Am Coll Cardiol 2008;
3. Barter PJ, Gotto AM, LaRosa JC et al, Treating to New Targets
Investigators. HDL cholesterol, very low levels of LDL cholesterol, and
cardiovascular events. N Engl J Med 2007; 357: 1301-10.
4. National Cholesterol Education Program (NCEP) Expert Panel on
Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
(Adult Treatment Panel III). Third Report of the National Cholesterol
Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment
of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report.
Circulation 2002;106: 3143-21.
5. Keech A, Simes RJ, Barter P et al. Effects of long-term fenofibrate
therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus
(the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61.
6. Keech AC, Mitchell P, Summanen PA, et al, FIELD study investigators.
Effect of fenofibrate on the need for laser treatment for diabetic retinopathy
(FIELD study): a randomised controlled trial. Lancet 2007;370:1687-97.
7. Colman P, Rajamani K, Li L-P et al. Benefits of long-term fenofibrate
therapy on amputations in type 2 diabetes mellitus in the FIELD trial.
Presented at the European Association for the study of Diabetes (EASD), Rome,
8.EffPage: 1 2 3 4 5 6 Related medicine technology :1
. February 2009 Mayo Clinic Womens HealthSource Highlights Diabetes and Heart Disease, Going Vegetarian and Tinnitus2
. MannKind Corporation to Review Positive Results From Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes3
. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals4
. Epidemics of Both Type 1 Diabetes (Insulin Dependent) and Type 2 Diabetes (Obesity Related) Are Linked to Immunization5
. Overweight Siblings of Children With Type 2 Diabetes Likely to Have Abnormal Blood Sugar Levels6
. Patient Recruitment Begins in India for Phase 3 Diabetes Trial7
. Opportunities to Highlight Type 1 Diabetes in November8
. Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Societys Eighth Annual Meeting (November 13-15, 2008; Bethesda, Maryland)9
. FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes10
. TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program11
. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes